noncardiac surgery for pt with CA stents Dr[1]. Leung

  • 格式:pdf
  • 大小:170.37 KB
  • 文档页数:4

2009年麻醉年会投稿(田穗荣)作者姓名:田穗荣,医学博士(Name in English: Tina Leung, MD )工作单位:美国纽约市Saint Vincents Hospital and Medical CenterNew York Medical CollegeDepartment of Anesthesiology120 W 12th StreetNew York, NY 10011USA联系地址:31-71 43rd StreetAstoria, NY, 11103, USA (美国)邮编: 11103 USA (美国)联系电话:917-365-0332电子邮件地址:tinaleung@论文标题:冠状动脉支架病人行非心脏手术的管理Non-cardiac Surgery for Patients with Coronary Artery Stents论文分类:临床麻醉与研究(麻醉并发症、危重医学)Non-cardiac Surgery for Patients with Coronary Artery StentsTina Leung, MD Saint Vincents Hospital and Medical Center, New York Medical College.New York USA Case PresentationsCase#1: A 70-year-old female with past medical history of hypertension and diabetes was admitted to the hospital for a diagnosis of colon cancer, for which a colectomy was scheduled. However, her preoperative cardiac work-up showed a positive stress test with reduced left ventricular (LV) ejection fraction. In the stress test, the tomographic imaging using technetium 99m revealed reversible perfusion defect involving anterior and anterior septal segments of LV wall; echocardiography showed severe hypokenesis/akenesis noticeable in the same LV wall segments. Those findings indicated severe stenosis of left anterior descending coronary artery (LDA). Due to the high perioperative cardiac risk, she underwent a percutaneous coronary intervention with a bare-metal stent implanted into the LAD. To prevent stent thrombosis antiplatelet medications of aspirin and clopidogrel (plavix, a thienopyridene class drug) were administered. The oncologic surgeon felt that it was urgent to proceed to the colectomy as the relentless progress of the colon caner.How would you manage this patient with concerns of the newly deployed stent and antiplatelet agents administration?Case #2: 75-year-old male with past medical history of hypertension and coronary artery disease was admitted to the hospital due to the recent diagnosis of benign prostate hypertrophy, for which an urologist recommended a transurethral resection of the prostate. However, four months prior to the current hospitalization, he had undergone a percutaneous coronary intervention with drug-eluting stents placed for treatment of the multivessels coronary artery disease. Since then, he had been taking dual antiplatelate medications including aspirin and plavix in order to reduce the risk of stent thrombus formation.How do we manage this patient in view of drug-eluting stents implantation and dual untiplatelet agents on board?DiscussionAs population aging, more and more elderly patients with coronary artery disease undergo percutaneous coronary intervention (PCI). Of the more than 2 million patients undergoing PCI annually, more than 90% will receive intra-coronary stents. Approximately 5% of patients in this group will require non-cardiac surgery (NCS) within the first year after stenting, and an increasing number will present for surgery thereafter.There are two types of coronary artery stents, bare-metal stents (BMSs) and drug-eluting stents (DESs). Histologic date for both animals and humans revealed that near-complete endothelialization of BMSs occurs rapidly, within 2-6 weeks of implantation, whereas endothelialization of DESs is significantly delayed for many months.Stent thrombosis is a catastrophic complication of PCI with stents that results in myocardial infarction in 40 -60% and death in 15-45%. Administration of dual antiplatelet therapy, consisting of aspirin and a thienopyrdine as clopidogrel, during the period of stent endothelialization effectively reduces the risk of stent thrombosis to < 1%. It is now recognized that premature discontinuation of dual antiplatelet therapy during the critical period is a major independent risk factor for stent thrombosis. A multicenter, prospective study indicates that the 9-month risk of cumulative stent thrombosis was nearly 90-fold higher in DES patient who prematurely discontinued dual antiplatelet therapy compared with those did not. Timing of the stent thrombosis appears to be delayed in patients with DES. Late (1 to 12 months) stent thrombosis was reported to occur in 0.19% of patients in a large DES registry.Nuttall G, et al. reported the incidence of major adverse cardiac events (MACEs) is lowest when NCS was performed 90 days after PCI with BMS placement. The MACEs is defined as the composite of death, myocardial infarction, stent thrombosis and repeat revascularization. In Nuttall’s study, the frequency of MACEs were 0.5%, 3.8%, and 2.8% when NCS were performed < 30 days, 31-90 days and > 90 days after PCI with BMSs, respectively. Univariate and multivariate analyses showed the shorter time interval between PCI with BMS and NCS significantly increased the risk of MACEs. Rabbitts et al. found that the frequency of MACEs was not to be significantly associated with the time between NCS and PCI with DES (Rates of MACEs 6.4, 5.7, 5.9 and 3.3% at 0-90days, 91days-180days, 181days-365days, and 366days-730 days after PCI with DES, respectively), but observed rates of MACEs were lowest if NCS performed 1 year after PCI with DES. Both studies show that bleeding complications were few and were not associated with antiplatelet therapy.Recommendations for patients with coronary stents undergo NCSThe 2007 Science Advisory recommends the course of thienopyridine therapy as follows: o Bare-metal stents: minimum of 1 montho Drug-eluting stents: 12 monthsThe 2007 ACC/AHA Guidelines recommends delaying elective NCS within thefollowing time periods:o Bare-metal stents: 4-6 weekso Drug-eluting stents: 12 monthsWhen surgery cannot be postponed and thienopyridine therapy must be interrupted: o Patients with new coronary stents, aspirin therapy should be continued throughoutthe perioperative period, if possible.o Thienopyridine therapy should be restarted as soon as possible after theprocedure.In patients who are undergoing PCI and are likely to require invasive or surgicalprocedures within the next 12 months, a bare-metal stent should be used.Surgeons must be made aware of the potentially catastrophic risks of prematurediscontinuation of thienopyridine therapy. The surgeon should contact the patient’scardiologist if issues regarding the patient’s antiplatelet therapy are unclear.Consideration should be given to continue dual antiplatelet therapy perioperativelybeyond the recommended time frame in any patient at high risk for stent thrombosis.Even after thienopyridine has been discontinued, try to continue aspirin therapyperioperatively in any patient with drug-eluting stent.Timing is every thing! The current studies confirm the guidelines that recommend delaying elective non-cardiac surgery for at least 6 weeks after BMS and one year after DES placement but cautions that some risk does extend beyond these time frames. Patients within the 6-week and 1-year vulnerable period after BMS and DES stent placements, as well as patients with high-risk stent thrombosis procedures (off label indications, e.g., long bifurcational left main or vein graft lesions) who are beyond these time points, should also continue clopidogrel therapy through the perioperative period unless they are at high risk for bleeding into a closed space, e.g., intracranial surgery.References1)Rabbitts et al. Anesthesiology, 2008; 109:596-6042)Nuttall G, et al, Anesthesiology, 2008; 109:588-953)AHA/ACC/SCAI/ACS/ADA Science Advisory, Circulation, 2007:115;813-84)ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care forNon-cardiac Surgery: Circulation, 2007:116;e418-99。